Background: The PI3K pathway is the most commonly activated signaling pathway in human cancer. The loss of PTEN further contributes to the tumorigenic impact of the active PI3K pathway, and have direct effect on prognosis of breast cancer. Although many small molecules are used in clinic to target the PI3K pathway, only minority of breast cancer patients respond to these drugs. This study identified the role of a deubiquitinating enzyme, USP10 in the regulation of PI3K pathway in breast cancer.
http://ift.tt/2CZEIKq
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου